A. Gadducci et al., EPIDOXORUBICIN AND LONIDAMINE IN REFRACTORY OR RECURRENT EPITHELIAL OVARIAN-CANCER, European journal of cancer, 30A(10), 1994, pp. 1432-1435
Lonidamine (150 mg x 3 day orally, days 1-5) plus high dose epidoxorub
icin (120 mg/m(2) intravenously, day 3) was tested in 26 patients with
refractory or recurrent epithelial ovarian cancer, to assess the anti
-tumour activity and the toxicity of this combination of drugs. All pa
tients were evaluable for toxicity and 24 for tumour response. Two com
plete responses (8.3%) and six partial responses (25.0%) were recorded
for a total response rate of 33.3%. 6 of 8 responding patients were p
retreated with anthracyclines. Stable disease was obtained in 7 patien
ts (29.2%). Toxicity was acceptable; only 1 (3.8%) patient stopped che
motherapy because of a left ventricular ejection rate reduction > 20%.
The most relevant side-effect was leucopenia (grade 3-4, 34.6%). In c
onclusion, the association of lonidamine and high-dose epidoxorubicin
has promising activity as second-line treatment in patients with refra
ctory or recurrent epithelial ovarian cancer.